219 results about "Hypromellose" patented technology

The invention relates to the technical field of medicines, in particular to a sustained-release coating as well as a preparation method and application thereof. The coating adopts a three-layer gradient structure design and comprises an inner layer coating, a middle layer coating and an outer layer coating, and the layers are compounded and matched through ethyl cellulose and hydroxypropyl methylcellulose with different molecular weights and are combined with talcum powder filling amount with gradient decreasing and a triethyl citrate plasticizer, so that accurate regulation and control of drug release are realized. Through hierarchical swelling-diffusion dynamic balance, burst release is inhibited, the inner layer has high talcum powder content to resist initial swelling stress, the outer layer has low filling amount to maintain hydrophobic continuity, interface defects are reduced in combination with high-temperature curing, and the release stability and long-term storage performance of drugs such as dihydroergoline mesylate are remarkably improved; the problems of sudden release, damp-heat sensitivity, impurity generation and the like of a traditional single-layer coating are solved.

The invention relates to a composite hydroxypropyl methylcellulose skeleton sustained-release material and a preparation method thereof, and belongs to the technical field of drug sustained release. The sustained-release material is prepared from 70 to 90 parts of hydroxypropyl methylcellulose (HPMC), 10 to 20 parts of sodium alginate, 8 to 15 parts of chitosan, 0.1 to 0.2 part of Omega-3 fatty acid, 0.05 to 0.06 part of vitamin D, 2.5 to 5 parts of soluble calcium salt-zinc salt composite cross-linking agent, 0.5 to 1.5 parts of hydrolyzable cross-linking agent, 3 to 10 parts of enzyme sensitive auxiliary material, 1 to 5 parts of pore-foaming agent and 2 to 8 parts of hydrophobic blocking agent. The preparation method comprises the steps of raw material pretreatment and dry mixing, active component dispersion liquid preparation, wet granulation and primary cross-linking, secondary cross-linking and drying, vacuum drying and size stabilization, curing and packaging and the like. The sustained-release material provided by the invention has the advantages of controllable drug release rate, good mechanical strength and biodegradability, is suitable for sustained-release delivery of Omega-3 fatty acid, vitamin D and other active components, and can improve the bioavailability and stability of drugs.

The present invention provides a betahistine antioxidant tablet and a preparation method thereof, the betahistine antioxidant tablet comprises: a first zone comprising anhydrous citric acid, microcrystalline cellulose and hydroxypropyl methylcellulose; the middle buffer area is a sodium alginate aqueous solution coating; a second zone including calcium carbonate, betahistine, and microcrystalline cellulose; the first zone is located at the top of the tablet, the second zone is located at the bottom, and the buffer zone physically isolates the first zone from the second zone. The first zone, the buffer zone and the second zone are designed to form a sandwich structure, oxidation resistance is realized through dual mechanisms of physical isolation and chemical neutralization, and CO2 generated by reaction of food-grade citric acid and calcium carbonate is used for physically replacing oxygen.

The invention provides an additive composition for promoting itraconazole absorption, and the additive composition is prepared from the following components in parts by mass: 20 to 40 parts of modified hydroxypropyl methylcellulose acetic acid succinate, 10 to 25 parts of copovidone, 5 to 15 parts of N-capryloyl sodium salicylate, 2 to 8 parts of nano silicon dioxide and 3 to 10 parts of polyoxyethylene-polyoxypropylene segmented copolymer. According to the additive composition disclosed by the invention, the problems of dissolution rate, bioavailability and stability of the itraconazole oral preparation are comprehensively solved through polymer modification, compounding synergy and parameter optimization, and the process cost is remarkably lower than that of the prior art.

The invention relates to the field of pharmacy, and discloses a felodipine sustained release tablet and a preparation method thereof.The felodipine sustained release tablet comprises a tablet core and a film coating layer wrapped outside the tablet core, and the tablet core comprises the following components in parts by mass: 3.5-5.0 parts of felodipine nanocrystals; 50 to 65 parts of modified hydroxypropyl methylcellulose; the preparation method comprises the following steps: S1, preparing felodipine nanocrystals: dissolving felodipine in an organic solvent, and carrying out anti-solvent precipitation and high-pressure homogenization treatment, so as to obtain a nanocrystal suspension; drug nanocrystals are embedded between silicate layers through an ultrasonic embedding technology, and burst release is inhibited by combining physical confinement and electrostatic adsorption; the gradient pore skeleton constructs a pore layer-by-layer decreasing structure through fluidized bed multi-temperature zone deposition, the release rate is accurately regulated and controlled, and collapse is avoided; the ionic liquid stabilizer is introduced, and the problems of nanocrystal aggregation and degradation are synchronously solved through hydrogen bond anchoring and an antioxidant function.

The present invention relates to an ophthalmic preparation. The ophthalmic preparation comprises: penehyclidine hydrochloride, phosphate buffer, sodium chloride and hypromellose; wherein, based on the total volume of the ophthalmic preparation, the concentration of the phosphate buffer is not higher than 25 mM and not 0 mM, the mass-volume ratio of penehyclidine hydrochloride is 0.01% - 2%, and the mass ratio of penehyclidine hydrochloride to sodium chloride is (0.011 - 0.85):1. The ophthalmic preparation of the present invention has the advantages of low irritation and high stability.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to nitrogen hydrochloride # imgabs0 # stine eye drops and a preparation process thereof, the nitrogen hydrochloride # imgabs0 # stine eye drops comprise 0.05% of nitrogen hydrochloride # imgabs1 # stine, 0.2-0.3% of hydroxypropyl methylcellulose, 0.1-0.2% of edetate disodium, 0.12-0.15% of an isoosmotic adjusting agent, 0.04-0.07% of a preservative and 0.005-0.0075% of choline aromatic folic acid; the nitrogen hydrochloride # imgabs2 # stine eye drops prepared by the preparation method disclosed by the invention have the advantages that the adsorption of nitrogen hydrochloride # imgabs3 # stine on a low-density polyethylene bottle is well inhibited under the condition of visible light, and the reduction of the concentration of nitrogen hydrochloride # imgabs4 # stine in the eye drops is remarkably prevented, so that the medication safety is improved. Besides, the added cholinofolic acid and hydroxypropyl methylcellulose have small irritation to eyes under a specific ratio, and can also have a large enough contact angle with the eyes of rabbits at high temperature, so that the retention property of the eye drops on the eyes can be improved, and the drug effect can be favorably exerted.

The invention relates to the technical field of pet medicine research and development, and particularly discloses an emotion relieving capsule preparation method based on a composite formula, the method comprises the following steps: mixing lavender extract and gamma-cyclodextrin to obtain embedding modified micro powder, carrying out enzymolysis on L-theanine to prepare powder, cross-linking gamma-aminobutyric acid and sodium alginate to obtain a nano composite carrier, and carrying out freeze drying on the nano composite carrier to obtain the emotion relieving capsule based on the composite formula. Mixing the three components to prepare a slow-release composite base material, mixing the slow-release composite base material with vitamin B6 and the like, sieving, finally filling into a hydroxypropyl methylcellulose hollow capsule shell, and coating with a film to prepare the capsule. Parameters such as raw material proportion and reaction conditions are definitely limited in each step. According to the capsule, the emotion of pets is relieved through a compound formula and cooperation of multiple components, the preparation method is scientific and reasonable, the product quality is controllable, the emotion problem caused by factors such as environment and living habits of the pets can be effectively solved, and the capsule has good application prospects.

The invention discloses a sustained and controlled release hydroxypropyl methylcellulose hollow capsule, and relates to the technical field of capsules, in order to realize a long-term sustained and controlled release effect of a drug, a hard shell of the capsule is improved, and antibacterial modified polysaccharide is added into raw materials, so that the compactness and barrier property of the capsule shell after curing and drying are improved, and the sustained and controlled release effect of the drug is improved. The drug protection performance is improved; in addition, in consideration of the fact that part of medicine capsules can be stored in medicine bottles which are taken for multiple times, the guanidyl and chitosan structures added into the prepared hollow capsule shell can provide excellent antibacterial and anti-pollution capacity for the capsules, growth and pollution of infectious microbes are avoided, and the efficacy of the medicine is maintained for a long time.

The invention provides a dexketoprofen trometamol oral solution and a preparation method thereof. According to the dexketoprofen trometamol oral solution, polyethylene glycol 400 and hydroxypropyl methylcellulose are used as stabilizing agents, methylparaben and propyl hydroxybenzoate are used as bacteriostatic agents, sucralose and ammonium glycyrrhizinate are used as sweetening agents, essence is used as a flavoring agent, and the pH value of the solution is controlled to be 6.2-6.8 through a pH value regulator. The increase of the impurity A, the impurity B, the impurity C, the impurity E and the total impurity is obviously reduced, so that the product stability is obviously improved.

The disclosed composition consists of 15 mg Ferula asafetida (Hing) oil as an active ingredient, 85 mg Frankincense oil and 400 mg coconut oil as in-active ingredients in an enteric coated HPMC capsule form. The process of preparation consists of steps of blending asafetida (hing) oil with Frankincense oil and coconut oil followed by dispensing the blended oils into empty HPMC capsule shell, which are automatically filled in liquid filling machine. Further a banding solution containing 0.025 ml HPMC (surfactant), 2.8 mg IPA (Binding Agent) and 0.03 mg Chocolate brown color (colorant) are filled into the bath of band sealing machine at room temperature where the hing oil containing capsules are band sealed. The disclosed oral formulation in the form of HPMC capsule is natural, low cost, highly efficacious and quick in management primary dysmenorrhea.

The invention belongs to the technical field of cosmetics, and particularly relates to a mask formula and a processing method thereof, the mask formula takes natural active ingredients as a core, and multiple skin care advantages are realized through scientific proportioning and an innovative process. A film forming system adopts a sodium alginate and hydroxypropyl methylcellulose compounding technology to form an air-permeable film, so that the air-permeable film can be tightly attached to the skin to promote absorption, and the skin stuffiness feeling of a traditional mask is avoided; cold-pressed camellia-seed oil is selected as a matrix, high-content oleic acid of the cold-pressed camellia-seed oil is highly matched with a sebum structure, and a bionic lipid barrier is formed by matching with ceramide, so that the water locking and repairing capability is remarkably improved. Microencapsulated nicotinamide and concentrated portulaca oleracea extract are creatively applied in an active system to achieve synergistic interaction, the microencapsulated nicotinamide continuously whitens skin and fades spots through a slow release technology, and the concentrated portulaca oleracea extract contains flavonoid compounds to accurately relieve inflammation and reduce sensitivity risks.

The invention discloses a mianserin hydrochloride tablet prepared in a wet granulation mode. The mianserin hydrochloride tablet is prepared from mianserin hydrochloride anhydride, calcium hydrogen phosphate, corn starch, hydroxypropyl methylcellulose, colloidal silicon dioxide, magnesium stearate and a film coating agent. According to the mianserin hydrochloride tablet and the preparation method thereof, the stability of the mianserin hydrochloride tablet is improved by using the high-concentration adhesive solution and optimizing the granulation parameter range, the problem that related substances are increased due to crystal transformation of active ingredients in the product preparation process is solved, and the medication safety of patients is better guaranteed.

The present invention provides a solid dispersion of compound 1 or a pharmaceutical salt thereof, comprising the compound 1 or the pharmaceutical salt thereof as an active ingredient and a carrier material, wherein the carrier material is selected from one, two, or more of polyvinylpyrrolidone (PVP), copovidone, polyvinylpyrrolidone-vinyl acetate copolymer, hydroxypropyl methylcellulose acetate succinate, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, hydroxypropyl methylcellulose, polyethylene glycol, and ethyl cellulose, enabling the drug to have good stability, dissolution, and therapeutic effects. The formulation of the present invention provides rapid drug release and can reduce the oral burden of large-dose tablets on menopausal patients, thereby improving treatment compliance and treatment efficiency.

The invention relates to the field of pharmaceutical preparations, and discloses a clopidogrel hydrogen sulfate tablet and a preparation method thereof, and the clopidogrel hydrogen sulfate tablet comprises the following components: 30-50 parts of clopidogrel hydrogen sulfate; 5-15 parts of a double-layer nano permeable membrane material; 3 to 12 parts of a pH sensitive release material; 5 to 12 parts of a supramolecular self-assembled nanoparticle material; 5 to 15 parts of a solubility regulator; 2-5 parts of an ionic crosslinking regulatory factor; 10 to 25 parts of an excipient; 0.5 to 2 parts of a lubricant; 0.5 to 2 parts of a stabilizer; the double-layer nano permeable membrane material comprises the following components in parts by weight: an inner layer material: 5-15 parts of hydroxypropyl # imgabs0 #-cyclodextrin; 3 to 10 parts of polyvinylpyrrolidone; an outer layer material: 2-8 parts of ethyl cellulose; and 2 to 10 parts of hydroxypropyl methylcellulose. The double-layer nano permeable membrane is combined with the pH-sensitive controlled release system, so that the dissolution rate of the medicine is adjustable, and accurate release in different pH environments is realized. The technical effects of improving the dissolution efficiency, optimizing medicine absorption and reducing individual differences are achieved.

The invention discloses a solid windshield washer fluid and a preparation method thereof, the solid windshield washer fluid comprises the following raw materials by weight: 45-55 parts of an acid source, 25-40 parts of sodium carbonate, 9-10 parts of a surfactant, 2.5-3.5 parts of a corrosion inhibitor, 1.5-2.5 parts of an antifoaming agent, and 3.5-4 parts of a builder; the washing assistant comprises sodium pyrophosphate, and the washing assistant further comprises one or more of hydroxypropyl methylcellulose and sodium stearyl fumarate. The preparation method of the solid windshield washer fluid comprises three steps of mixing, tabletting and slicing. The solid windshield washer fluid provided by the invention can achieve the effects of being good in cleaning effect, excellent in spreading performance and capable of protecting a windscreen wiper.

The present invention relates to the field of pharmaceutical formulations, and in particular to a fine granule and a preparation method therefor. The provided fine granule is a fine granule having core particles, a coating layer and an additional material layer. Hydroxypropyl cellulose and / or hydroxypropyl methylcellulose in a specific proportion are selected as a tackifier, and low-substituted hydroxypropyl cellulose is used as a disintegrating agent, so that the prepared fine granule has good particle compactness, disintegration performance and dissolution performance. An anti-adherent is homogenized during the preparation of the coating layer material, so that the prepared coating layer material has good anti-adhesion effect, and does not adhere in the particle coating process, thereby ensuring the integrity of the particles. A fluidized granulation coating machine is selected for preparation and coating of the core particles, thereby ensuring more uniform particle size distribution of the fine granule.

A rizatriptan microneedle patch, a preparation method therefor, and use thereof. The rizatriptan microneedle patch comprises a substrate and a needle body arranged on a surface of the substrate. The composition of the needle body comprises rizatriptan benzoate and a skeleton material. The skeleton material comprises a combination of dextran and trehalose, copovidone, a combination of polyvinyl alcohol and dextran, a combination of hypromellose and dextran, or a combination of sodium carboxymethyl cellulose and dextran. The rizatriptan microneedle patch has high mechanical strength and cumulative drug permeation.

The invention provides a sitagliptin and metformin sustained-release pharmaceutical composition as well as a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer, the sustained-release tablet core comprises an active ingredient metformin hydrochloride and a sustained-release framework material hydroxypropyl methylcellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises an active component sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methylcellulose in the sustained release tablet core is 50: (24-27). The composition utilizes a double-layer structure to realize double-phase release of the medicine; the microcrystalline cellulose is removed, and the specific ratio of the active component to the framework material is limited, so that the moldability and ideal dissolution behavior of the preparation are ensured while the tablet weight is remarkably reduced to improve the swallowing compliance, and the technical problem that the slow-release framework function is difficult to maintain under the condition that the weight of a high-drug-loading-capacity compound preparation is greatly reduced is successfully solved.

The invention belongs to the field of pharmaceutical preparations, and provides a medical composition for treating premature delivery and a preparation method thereof. The progesterone nanocrystal (D50 is 250-350 nm) and poloxamer 407 / 188 thermosensitive gel-forming system composite design is adopted, hydroxypropyl methylcellulose or carbomer 974P and a functional adhesion polymer (carbomer-cysteine or carbomer-catechol) are matched, the pH is adjusted to 4.0-4.5 through a lactic acid / sodium lactate buffer system, and the progesterone nanocrystal / poloxamer composite gel-forming agent is prepared. The excellent performance that the sol-gel transition temperature is 30-34 DEG C, the elastic modulus is not smaller than 150 Pa at 37 DEG C, the modulus retention rate is not smaller than 60% after the emulsion is diluted by 5-10 times, the adhesion work is not smaller than 0.60 N.s, and the anti-flushing retention rate is not smaller than 70% after the emulsion is diluted by 5-10 times is achieved. The invention solves the problem of synergy of high-modulus gel strength, rapid self-repairing ability and anti-dilution and anti-flushing stability, realizes unification of long-acting drug release and excellent biological adhesion performance in vagina physiological fluid dilution and mechanical flushing environments, and has wide clinical application value.

The application provides a sitagliptin and metformin hydrochloride sustained-release pharmaceutical composition and a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer; the sustained-release tablet core comprises active ingredients metformin hydrochloride and a sustained-release matrix material hydroxypropyl methyl cellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises active ingredients sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methyl cellulose in the sustained-release tablet core is 50:(24-27). The composition realizes double-phase release of drugs by using a double-layer structure; by removing the microcrystalline cellulose and limiting the specific ratio of active ingredients to the matrix material, the forming property of the preparation and the ideal dissolution behavior are ensured while the tablet weight is significantly reduced to improve the swallowing compliance, and the technical problem that a high drug loading compound preparation is difficult to maintain the function of the sustained-release matrix under a large amount of weight reduction is successfully solved.

The invention provides an effervescent tablet containing active probiotics and a preparation method thereof, and relates to the technical field of food and health care product processing. The preparation method of the effervescent tablet containing the active probiotics comprises the following steps: (1) acid granulation: coating an acid material with hydroxypropyl methylcellulose, and mixing with an adhesive and PEG 6000 for granulation; (2) alkali granulation: coating an alkali material with ethyl cellulose, mixing the coated alkali material with microcrystalline cellulose and an adhesive for granulation, and mixing with PEG (Polyethylene Glycol) 6000; (3) mixing the probiotic mixture by adopting an equivalent incremental method; (4) pre-pressing 30-40 kN of the acid particles to obtain an acid layer; and then sequentially filling a probiotic mixture and alkali particles, and finally pressing under the pressure of 50-60kN. According to the effervescent tablet containing the active probiotics, a double-layer tabletting technology is adopted, the survival rate of viable probiotics in the effervescent tablet is increased, and the disintegration time limit is shortened; and uniform bubbles and clear solution in the effervescing process are ensured.

The invention relates to the technical field of dairy product processing, and particularly discloses a production process and device of camel milk slices. The production process of the camel milk slice comprises the following steps: sterilizing camel raw milk, cooling to 1-4 DEG C, and uniformly mixing with lactase to obtain pretreated camel milk; centrifuging the pretreated camel milk to remove impurities to obtain purified camel milk; heating the purified camel milk to 8-10 DEG C, centrifuging at a high rotating speed under ultrasonic waves, and filtering with a filter membrane to obtain filtered milk liquid; concentrating the filtered milk liquid under the conditions that the temperature is less than or equal to 40 DEG C and the vacuum degree is-90 to-100 kPa until the solid content is 45 to 50 percent, so as to obtain concentrated milk liquid; adding micro-capsule bifidobacteria into the concentrated milk liquid, performing spray drying to obtain camel milk powder, uniformly mixing the camel milk powder with hydroxypropyl methylcellulose, performing tabletting, spraying whey protein-vitamin E composite liquid, and performing curing to obtain a coating layer to obtain the camel milk tablets. The camel milk powder viscosity and the surface roughness of the semi-finished product of the milk tablet can be reduced, and the adhesive force of the coating layer is improved.

The invention relates to the technical field of medicinal high polymer material synthesis, in particular to hydroxypropyl methylcellulose (HPMC) and a preparation method thereof, the method comprises the following steps: (1) pre-swelling treatment: mixing cotton powder with an isopropanol aqueous solution with the mass concentration of 10-20% according to the mass ratio of 1: (4-6), and pre-swelling at 20-25 DEG C for 30-60 minutes to obtain pre-swelled cotton powder; and (2) alkalization. (3) etherification: adding the etherification reagent into a reaction kettle, and enabling the etherification reagent to react with the alkalized refined cotton powder. (4) separating and drying; and (5) crushing: performing multi-stage gradient freeze-dried powder crushing on the dried material. And (6) obtaining a final product: mixing and packaging the crushed product. The HPMC product which is low in bulk density, fine in particle size and extremely small in batch-to-batch difference is prepared through the method, and it is ensured that the HPMC product has excellent and stable slow release performance when serving as a slow release framework material.

The present application relates to the technical field of pharmaceutical preparation, and provides a calcium carbonate tablet, which comprises the following raw materials in parts by weight: 700-800 parts of calcium carbonate, 80-100 parts of corn starch, 15-25 parts of low-substitution hydroxypropyl cellulose, 1.5-2.5 parts of polysorbate-80, 7-9 parts of protein sugar, 3-5 parts of hypromellose, 2.5-3.0 parts of magnesium stearate and 15-25 parts of sodium carboxymethyl starch; wherein the calcium carbonate is selected from calcium carbonate with a particle size of 40-80 μm; the low-substitution hydroxypropyl cellulose and the sodium carboxymethyl starch are disintegrants, and the ratio of the amount of the low-substitution hydroxypropyl cellulose to that of the sodium carboxymethyl starch is 1:1. The present application also provides a preparation method of the calcium carbonate tablet. The calcium carbonate tablet has the advantages of short disintegration time, high dissolution rate, good bioavailability and good stability.

The application discloses a white hypromellose hollow capsule, a preparation method and application thereof, and the composition of the hollow capsule comprises the following components in percentage by weight: 10-35 parts of hypromellose, 0.1-3 parts of a gelling agent, 0.2-3 parts of a complexing agent, 0.1-3 parts of a phosphate, 0.05-1 parts of an emulsifying agent, 0.05-1 parts of a coagulant, 0.01-1 parts of starch, 0-2 parts of a pigment, and the rest is water. The application discloses a white hypromellose hollow capsule with a whitening effect, which is obtained by adding the complexing agent and the phosphate and controlling the drying temperature and the drying time, and does not contain white pigment light-proof agents such as titanium dioxide, zinc oxide, calcium carbonate, barium sulfate and magnesium oxide. The hollow capsule has the advantages of uniform surface, good gloss, good uniformity, good light-proof property, small capsule weight difference, market demand satisfaction, and application in the fields of medicines and health products.

The present invention relates to a dry granulation process for preparing a solid pharmaceutical composition comprising Tenofovir alafenamide or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients, and its use in the treatment of for the treatment of chronic hepatitis B (CHB). The pharmaceutical composition comprises at least a disintegrant as pharmaceutical acceptable excipient for increasing the stability of the Tenofovir alafenamide and tablet coating material comprising hypromellose and hydroxypropyl cellulose, thus surprisingly improved impurity values and also improved dissolution profile has been obtained.

The invention discloses a coenzyme Q10 nanoparticle, which is prepared from the following raw materials in parts by weight: 0.16 to 0.2 part of coenzyme Q10, 8 to 10 parts of zein, 0.2 to 0.4 part of ethyl cellulose, 1 to 2 parts of sodium alginate and 0.2 to 0.4 part of hydroxypropyl methylcellulose. The invention also discloses a preparation method of the coenzyme Q10 nanoparticle. The preparation method comprises the following steps: dissolving coenzyme Q10, ethyl cellulose and zein in ethanol to obtain a solution A; dropwise adding the solution A into a mixed aqueous solution of sodium alginate and hydroxypropyl methylcellulose, stirring, and freeze-drying to obtain the coenzyme Q10 nanoparticles. The coenzyme Q10 nanoparticles disclosed by the invention have good encapsulation efficiency and hydrophobicity, and can keep water stable and improve the stability of the coenzyme Q10 nanoparticles; in addition, agglomeration of the nano-particles can be avoided, so that the nano-particles can be uniformly dispersed with other components and auxiliary materials to be matched for use.

The invention provides a sitagliptin and metformin sustained release tablet and a preparation method thereof. The sitagliptin and metformin sustained-release tablet sequentially comprises a metformin tablet core, a sitagliptin quick-release layer and a gastric-soluble coating layer from inside to outside, and the sitagliptin quick-release layer comprises sitagliptin phosphate monohydrate, a basic nitrogen atom shielding agent, hydroxypropyl methylcellulose, propyl gallate, kaolin and polyethylene glycol. Wherein the basic nitrogen atom shielding agent is mixed in the sitagliptin phosphate monohydrate and is used for shielding protection of trifluorophenylpiperazine ring tertiary nitrogen and beta-aminopropionic acid residue primary amino in the sitagliptin phosphate monohydrate. According to the sitagliptin and metformin sustained-release tablet, the dissolution rate of sitagliptin can be increased, so that the drug effect of the sitagliptin and metformin sustained-release tablet is ensured.

The present invention relates to the technical field of hollow capsules, and specifically to a production process of enteric-coated plant hollow capsules. First, the present invention uses hypromellose as the main material, and carrageenan, Tween 80, and sodium alginate as auxiliary materials. After mixing the main material, auxiliary materials and water, hollow capsules are obtained through processes such as dipping, forming, drying, demolding, and cutting; the present invention also modifies chitosan with sodium palmitate to obtain chitosan-palmitate with hydrophobic properties; a coating solution is prepared by mixing chitosan-palmitate and hypromellose acetate succinate, and the hollow capsules are coated to obtain the finished product. The enteric-coated plant hollow capsules prepared by the present invention have a high finished product rate, a low moisture absorption rate, a long disintegration time in gastric acid, ensure the release of effective components in the upper part of the small intestine, and increase the absorption efficiency.